Sponsors (2)
Introduced March 5, 2025 by H. Morgan Griffith · Last progress March 5, 2025
The bill increases transparency and oversight of advisory committee conflicts and royalty-related interests—strengthening accountability and public trust—at the cost of added administrative burdens, privacy risks for individuals, and a risk of expanding reporting requirements to peripheral panels.
Taxpayers and the public: regular GAO listings and annual agency reports will create routine, public records of covered advisory members and royalty payments, improving accountability and enabling targeted congressional oversight.
Scientists, healthcare professionals, and the public: members of key public-health advisory committees must file financial disclosures, increasing transparency about conflicts of interest and improving public trust in advisory recommendations.
Federal ethics offices and congressional oversight: agencies will receive more information when advisory committee members obtain waivers, making oversight of conflicts and exemptions more effective.
Federal employees, advisory members, contractors, and taxpayers: the bill creates additional recurring administrative and compliance burdens—agencies, contractors, grantees, and individual experts will spend time and resources to collect, review, and report disclosures and royalty data.
Federal employees, scientists, and advisory participants: publishing names and royalty amounts online and broadly sharing disclosures with Members of Congress raises privacy risks and could expose individuals to targeted harassment or unwanted disclosure of sensitive personal data.
Advisory committee members and participants: the GAO's temporary authority to designate additional committees could sweep peripheral panels into reporting requirements, imposing obligations on participants not originally intended and broadening compliance scope.
Based on analysis of 4 sections of legislative text.
Expands financial-disclosure and COI rules to cover many public-health advisory committee members, requires GAO listings and congressional notice of ethics waivers, and adds royalty checks for contractor COI reviews.
Expands federal ethics and conflict-of-interest rules to increase transparency about royalties and public-health advisory committee finances. It requires more members of executive-branch public-health advisory committees to file financial disclosures, directs the Government Accountability Office (GAO) to publish and maintain a list of covered committees for a limited time, mandates quicker congressional notification when ethics waivers or certain conflict exemptions are granted, and requires federal contractor/grantee conflict reviews to explicitly check royalties paid in the prior year with annual agency reporting to oversight committees. Also directs agencies (and the FAR Council/OMB) to update regulations to implement royalty checks in COI reviews, sets reporting deadlines (GAO list in 180 days; agency reports within one year and annually thereafter), and contains a severability clause so other provisions remain if a part is struck down by a court.